Raloxifene 60 mg (Film-coated tablet)

1. Description: Clinical summary

Raloxifene 60 mg (active compound: raloxifene hydrochloride equivalent to 60 mg raloxifene) is an oral selective estrogen receptor modulator (SERM) indicated primarily for:

• Prevention and treatment of postmenopausal osteoporosis.
• Reduction of risk of invasive breast cancer in postmenopausal women at increased risk and in postmenopausal women with osteoporosis.

Raloxifene binds estrogen receptors and produces tissue-selective estrogenic and antiestrogenic effects: it has estrogen-like (agonist) effects on bone and lipid metabolism and antiestrogenic (antagonist) effects in breast tissue. Clinical benefits include reduced vertebral fracture risk and decreased incidence of estrogen receptor–positive invasive breast cancers in selected populations. Raloxifene is intended for use in postmenopausal women; it is contraindicated in pregnancy and lactation.

2. How does Raloxifene 60 mg work?

Mechanism of action (brief, clinical):

• Raloxifene is a selective estrogen receptor modulator (SERM). It binds to estrogen receptors (ERα and ERβ) and modulates receptor conformation and gene transcription in a tissue-selective manner.
• Bone: acts as an estrogen agonist, reducing bone resorption and turnover, thereby increasing or preserving bone mineral density and reducing risk of vertebral fractures.
• Breast: acts as an estrogen antagonist, inhibiting estrogen-stimulated proliferation of breast epithelium and reducing incidence of ER-positive invasive breast cancer.
• Uterus: unlike some other SERMs, raloxifene shows little or no estrogenic stimulation of the endometrium; it has not been shown to increase endometrial cancer risk the way tamoxifen can.
• Metabolism: raloxifene is extensively metabolized by conjugation (glucuronidation) and undergoes enterohepatic recirculation. It is not a major CYP450 substrate.

3. Dosage: Medical and varying usage guidelines

Standard dosing

• Adult (postmenopausal women): 60 mg orally once daily, with or without food. This is the approved dose for both osteoporosis treatment/prevention and breast cancer risk reduction.

Administration and missed dose

• Take at approximately the same time each day.
• If a dose is missed, take it as soon as remembered unless it is near the time of the next dose; do not double doses.

Duration of therapy

• Duration depends on clinical goals (fracture prevention, breast cancer risk reduction) and patient response. Periodic reassessment (bone mineral density testing, risk/benefit review) is recommended.
• For osteoporosis, concomitant adequate calcium and vitamin D intake is recommended.

Special populations

• Elderly: no dose adjustment necessary based on age alone.
• Renal impairment: no specific dose adjustment recommended for mild–moderate renal impairment; limited data in severe renal impairment—use clinical judgment.
• Hepatic impairment: use with caution in patients with hepatic dysfunction; raloxifene is extensively metabolized hepatically. Severe hepatic impairment has limited data—consult specialist guidance.
• Pediatric: not indicated.
• Men: not indicated.

Contraindications and precautions (dose-related relevance)

• Contraindicated in patients with current or past venous thromboembolism (deep vein thrombosis, pulmonary embolism).
• Contraindicated in pregnancy and lactation.
• Use with caution in women at high baseline risk of stroke or coronary events; consider individual cardiovascular risk.

Drug interactions (brief)

• Bile acid sequestrants (e.g., cholestyramine) can reduce raloxifene absorption; if needed, separate dosing (take raloxifene at least 1 hour before or 4–6 hours after the sequestrant).
• Raloxifene is not primarily metabolized by CYP450; major CYP-mediated interactions are not expected, but always review concomitant medications for additive thrombotic risk (e.g., estrogens).
• Concomitant use with other SERMs (e.g., tamoxifen) is generally avoided.

Monitoring and baseline assessments

• Baseline bone mineral density (DEXA) is recommended if treating osteoporosis.
• Assess baseline and periodic evaluation of risk factors for venous thromboembolism and stroke.
• Monitor for clinical signs/symptoms of thromboembolism, unexplained vaginal bleeding, and other adverse effects.

4. Side effects: Common and rare adverse effects

Common adverse effects (seen in clinical use)

• Hot flashes/night sweats
• Leg cramps
• Peripheral edema
• Arthralgia, muscle cramps
• Gastrointestinal symptoms (dyspepsia)
• Flu-like symptoms, infection (reported)
• Sweating

Uncommon to rare but serious adverse effects

• Venous thromboembolism (VTE): increased risk of deep vein thrombosis and pulmonary embolism. This is a serious, potentially life‑threatening risk and is a well-established adverse effect.
• Stroke: some studies suggest an increased risk of fatal stroke in postmenopausal women with existing coronary heart disease; overall stroke risk signal requires individual cardiovascular risk assessment.
• Hypersensitivity reactions: rare severe allergic events.
• Unexplained vaginal bleeding: any postmenopausal bleeding should be evaluated promptly.
• Other: in isolated reports, hepatic dysfunction or elevated liver enzymes have occurred (monitor if clinically indicated).

Patient counseling/adverse event warnings

• Seek immediate medical attention for signs of VTE: unilateral leg pain/swelling, warmth, redness; or pulmonary embolism: sudden unexplained shortness of breath, chest pain, coughing blood.
• Stop and notify provider for new or unusual vaginal bleeding.
• Discuss prolonged immobilization or major surgery: temporary discontinuation may be advised because of increased thrombotic risk—follow physician instructions.
• Inform patients that raloxifene does not prevent nonvertebral fracture as reliably as some other agents—discuss fracture risk profile.

5. Storage: HOW to store it

• Store at controlled room temperature, typically 20–25 °C (68–77 °F); brief excursions permitted (consult local labeling, often 15–30 °C / 59–86 °F).
• Protect from moisture and excessive heat.
• Keep in original packaging to protect from light and moisture (if provided).
• Keep out of reach of children and pets.
• Do not use beyond the expiration date on the package.

General note
This guide provides an evidence-based clinical overview of raloxifene 60 mg for educational purposes. It does not replace individualized medical advice. Dosing, monitoring, and decisions about use should be determined by a qualified healthcare professional based on a patient’s complete clinical status, comorbidities, and concomitant medications. If you have specific clinical questions (e.g., use in a patient with particular comorbidities or co-medications), share those details for more tailored guidance.